Chronic Kidney Disease Drug Pipeline: 114 Assets by Phase

How many chronic kidney disease drugs are in each phase of development?

Douglas Insights counts 32 chronic kidney disease candidates in Phase III, 28% of the 114 assets in development; Phase II holds 41 and Phase I holds 41.

Phase I/II candidates sit in the Phase I row and Phase II/III candidates in the Phase II row, so each chronic kidney disease asset appears in exactly one row. The 286 trials still recruiting or running carry 34% of the 834 registered trials in scope.

Which approved chronic kidney disease medicines are still in trials?

7 medicines already on the market are still being tested in chronic kidney disease Phase IV trials; Dapagliflozin has the most, with 40 registered trials.

Post-approval chronic kidney disease trials test new doses, new patient groups and head-to-head comparisons. They set the standard of care that every candidate in development will be measured against, so the paid review profiles each one.

How many chronic kidney disease trials are recruiting patients now?

152 chronic kidney disease trials are recruiting patients and 79 more have not started recruiting yet, out of 834 interventional trials in scope; together they make up 28% of the trial base.

Terminated, suspended and withdrawn chronic kidney disease trials stay in the trial base so that a stalled programme is visible, but a candidate whose only trials stopped is no longer counted as in development.

Which companies lead the chronic kidney disease pipeline?

AstraZeneca leads the chronic kidney disease pipeline with 8 candidates; the top 5 sponsors hold 26% of the 114 assets, and 68 sponsors run at least one.

Industry sponsors lead 390 of the 834 chronic kidney disease trials (47%); universities, hospitals and public funders lead the rest. A sponsor is credited with an asset when it is the lead sponsor on most of that asset's industry trials.

Which drug types and mechanisms dominate the chronic kidney disease pipeline?

Mechanism and drug-type classification for the 114 chronic kidney disease candidates is done by the research desk asset by asset, each with a cited source, and is published in the paid review together with the white-space map.

What chronic kidney disease trial readouts are coming next?

19 chronic kidney disease candidates in Phase II or later have a registered primary completion date in the next 12 months; the next three are below, each linked to its registry record.

Primary completion is the date a sponsor expects the last patient to finish the main measurement, so data usually follow within months. Dates marked estimated are the sponsor's own forecast on the registry and often move.

How many chronic kidney disease readouts fall in each quarter?

34 chronic kidney disease candidates in Phase II or later reach registered primary completion over the next eight quarters, with the most, 9, due in Q4 2027.

Each candidate is counted once, at its next readout. The paid catalyst calendar names every readout with its trial, sponsor and design, adds filings and regulatory decisions, and runs 24 months ahead.

Which countries host the most chronic kidney disease trials?

United States hosts the most chronic kidney disease trials, with sites in 316 of the 834 studies (38%); trials in scope run in 89 countries in all.

A multinational chronic kidney disease trial is counted once in every country where it has a site, so the shares add up to more than 100%. Country spread shows where sponsors are building the evidence that regulators in each market will ask for.

Where are chronic kidney disease drugs being tested?

316 of the 834 chronic kidney disease trials (38%) have a site in the United States, 240 (29%) in Europe and 153 (18%) in China; 57 of the 114 candidates in development are tested in the US.

Each region's trials are the evidence its regulator will review: the FDA in the United States, the EMA (with the MHRA and Swissmedic) in Europe, the NMPA in China and the PMDA in Japan. A multinational chronic kidney disease trial counts once in every region where it has a site, so the shares add up to more than 100%. A candidate tested only outside the US and Europe is often a licensing opportunity for sponsors in those markets.

What has changed in the chronic kidney disease pipeline since the last update?

Since 3 Oct 2026, the chronic kidney disease pipeline count moved by +1 assets to 114, Phase III moved by +1 and the trial base by 0.

How does Douglas Insights count the chronic kidney disease pipeline?

Douglas Insights read 834 interventional trials registered on ClinicalTrials.gov for the conditions "chronic kidney disease", "diabetic kidney disease" and updated since 3 Oct 2021, then grouped every drug or biologic named in them into 114 unique candidates.

1. Code names, generic names and brand names of the same molecule are merged into one candidate, and every merge is reviewed by the research desk.
2. A candidate counts when it has a trial that is recruiting, running, or completed in the last 24 months, and at least one industry-sponsored trial.
3. Its phase is the highest phase among those trials; placebo, standard-of-care and comparator arms are not candidates.
4. Each figure on this page is drawn from one frozen dataset that passes ten checks before release, and the owner approves every edition.

Read the full approach on the research methodology page, or browse other Pharmaceuticals research.

Frequently asked questions about the chronic kidney disease pipeline

Research & citation

This review was researched, written and reviewed by the Douglas Insights Research Desk under the Douglas Insights editorial standards. Material errors are logged in the corrections log. No section is sponsored.

Adjacent coverage